Journal
CNS NEUROSCIENCE & THERAPEUTICS
Volume 17, Issue 2, Pages 118-132Publisher
WILEY
DOI: 10.1111/j.1755-5949.2010.00162.x
Keywords
Antipsychotics; Dopamine D2 receptor; Dopamine supersensitivity; D2High receptors; Psychosis; Schizophrenia
Categories
Ask authors/readers for more resources
P>Background: The dopamine D2 receptor is the common target for antipsychotics, and the antipsychotic clinical doses correlate with their affinities for this receptor. Antipsychotics quickly enter the brain to occupy 60-80% of brain D2 receptors in patients (the agonist aripiprazole occupies up to 90%), with most clinical improvement occurring within a few days. The D2 receptor can exist in a state of high-affinity (D2High) or in a state of low-affinity for dopamine (D2Low). Aim: The present aim is to review why individuals with schizophrenia are generally supersensitive to dopamine-like drugs such as amphetamine or methyphenidate, and whether the D2High state is a common basis for dopamine supersensitivity in the animal models of schizophrenia. Results: All animal models of schizophrenia reveal elevations in D2High receptors. These models include brain lesions, sensitization by drugs (amphetamine, phencyclidine, cocaine, corticosterone), birth injury, social isolation, and gene deletions in pathways for NMDA, dopamine, GABA, acetylcholine, and norepinephrine. Conclusions: These multiple abnormal pathways converge to a final common pathway of dopamine supersensitivity and elevated D2High receptors, presumably responsible for psychotic symptoms. Although antipsychotics alleviate psychosis and reverse the elevation of D2High receptors, long-term antipsychotics can further enhance dopamine supersensitivity in patients. Therefore, switching from a traditional antipsychotic to an agonist antipsychotic (aripiprazole) can result in psychotic signs and symptoms. Clozapine and quetiapine do not elicit parkinsonism or tardive dyskinesia because they are released from D2 within 12 to 24 h. Traditional antipsychotics remain attached to D2 receptors for days, preventing relapse, but allowing accumulation that can lead to tardive dyskinesia. Future goals include imaging D2High receptors and desensitizing them in early-stage psychosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available